Tubulin inhibitor payloads
Tubulin inhibitor payloads were the first generation of modern ADC payloads: drugs that jam the cell's scaffolding so it cannot divide. Nerve and eye side effects are typical.
Auristatins (MMAE, MMAF) and maytansinoids (DM1, DM4) bind tubulin and arrest mitosis, so they work best in rapidly dividing tumours. Whether the released form crosses membranes decides the bystander effect: MMAE and DM4 do, MMAF and DM1 do not. Peripheral neuropathy (MMAE), keratopathy (MMAF, DM4) and thrombocytopenia (DM1) are the characteristic toxicities. Most are substrates for P-glycoprotein.
Pages like this
not linked directly; found by shared links- Termmc-Val-Cit-PABC
Shares Tisotumab vedotin, Telisotuzumab vedotin, MMAE, Disitamab vedotin.
- TermMaleimidocaproyl (mc), non-cleavable
Shares MMAF, Belantamab mafodotin, Antibody-drug conjugate (ADC).
- TermSulfo-SPDB (disulfide)
Shares DM4, Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).
- PathwayDrug efflux pumps (ABC transporters)
Shares MMAE, Bystander effect (ADC), Drug efflux pumps (ABC transporters), Enfortumab vedotin.
- IdeaDose and schedule optimisation trials specific to antibody-drug conjugates
Shares Mirvetuximab soravtansine, Enfortumab vedotin, Payload (ADC), Antibody-drug conjugate (ADC).
- TermSMCC (thioether, non-cleavable)
Shares DM1, Trastuzumab emtansine, Antibody-drug conjugate (ADC).
- RoadmapADC roadmap: from Mylotarg to bispecific and dual-payload ADCs
Shares Telisotuzumab vedotin, Mirvetuximab soravtansine, Trastuzumab emtansine, Enfortumab vedotin.
- TermDXd
Shares Bystander effect (ADC), Drug efflux pumps (ABC transporters), Payload (ADC), Antibody-drug conjugate (ADC).